HIV/AIDS patients were treated, daily, with
MSAMS (50 mg/kg), MSAMS-stabilized Ampicillin trihydrate (7.5 mg/kg) and
immunace extra-protectionM? (1 tablet), for one month and then, with only MSAMS
and the immune stimulants. They were tested, monthly, for viral loads and CD4-
lymphocytes counts. Those whose viral loads became undetectable were tested for
HIV confirmation (antigens/antibody). Their mean-viral load increased (P =
0.020) from 1820.30 ± 868.75 to 2855.90 ± 960.98 after first month, before reducing
(P = 0.0.030) to: 1565.20 ± 743.17; 759.20 ± 473.65; 345.50 ± 115.01; 192.80 ±
97.40; 95.00 ± 55.80; 37.40 ± 26.46; 17.50 ± 16.88 (undetectable). Their
mean-CD4 count was 496.80 ± 194.39 (lymphopenia). It reduced (P = 0.008) to
263.90 ± 149.26 after first month, before increasing (P = 0.001) to: 507.90 ±
133.19; 692.70 ± 113.34; 840.20 ± 139.41; 1007.30 ± 163.50; 1537.10 ± 302.10;
1924.60 ± 247.45; 2707.00 ± 837.87 (lymphocytosis). Patients whose viral loads
became undetectable tested HIV-negative, one month after. CD4-lymphocytes
count, approximating to zero-viral load, calculated from equation (Y = 2297.80 － 1.4731X) of line of best fit of graph of their viral loads onCD4-lymphocytes
counts, was 1559.84/ml.
Yokoyama, M. (2011) Structural Mechanisms of Immune Evasion of HIV 1 gp 120 by Genomic Computational and Experimental Science. Uirusu, 61, 49-57. http://dx.doi.org/10.2222/jsv.61.49
[3]
Gentile, M., Adrian, T., Scheidler, A., Ewald,M., Dianzani, F., Pauli, G. and Gelderblon, H.R. (1994) Determination of the Size of HIV Using Adenovirus type 2 as an Internal Length Marker. Journal of Virological Methods, 48, 43-52.
http://dx.doi.org/10.1016/0166-0934(94)90087-6
[4]
Brooks, G.F. (1998) Medical Microbiology. 21st Edition, McGraw Hill Education Inc., San Franscisco.
[5]
Cristina, E., Ivan, P. and Kevin, R. (2007) Nanomaterials and Nanoparticles: Sources and Toxicity. Biointerphases, 2, 17-21.
[6]
Ezeibe, M.C.O. and Ogbonna, I.J. (2015) Acquired Immune Deficiency Syndrome in Man and Animals—A Review. World Journal of AIDS, 5, 50-57. http://dx.doi.org/10.4236/wja.2015.51006
[7]
Ezeibe, M.C.O., Aleeyu, D., Ogbonna, I.J. and Kalu, E. (2016) Clinical Trial of Medicinal Synthetic Aluminum-Magnesium Silicate (Antivirt?) on Viral Loads and CD4-Lymphocytes Counts of HIV/AIDS Patients. World Journal of AIDS, 6, 37-41. http://dx.doi.org/10.4236/wja.2016.62005
[8]
World Health Organization (2007) Laboratory Guidelines for Enumerating CD4 T Lymphocytes in the Context of .HIV/AIDS.World Health Organization Regional Office for South-East Asia, New Delhi.
[9]
Galindo, L.A. and Cereso, P. (2006) Compositional Technical and Safety Specification of Clay to Be Used as Pharmaceutical and Cosmetic Products. Journal of Renal Nutrition, 2, 38-40.
[10]
Ezeibe, M.C.O. (2014) The Medicinal Synthetic Aluminum-Magnesium Silicate (Nanoparticles)—Antiviral Agent and Adjuvant to Chemotherapeutics. Federal Republic of Nigeria Patents and Designs Ref No.: NG/P/2012/639.
[11]
Murray, K.R. (2000) Harpers Biochemistry. McGraw Hill, New York.
[12]
Ezeibe, M.C.O., Ngene, A.A., Kalu, I.K., Ezeh, I.O., Mbuko, I.J., Ekwuruke, J.O., Anene, I., Amechi, B., Olowoniyi, P. and Ifekwe, I.F. (2014) Assessment of Antiretroviral Effects of a Synthetic Aluminum-Magnesium Silicate. BJMMR, 4, 1672-1679.
[13]
Ezeibe, M.C.O., Ijabo, O., Uzopuo, C., Okoroafor, O.N., Eze, J.I. Mbuko, I.J., Sanda, M.E., Animoke, P.C. and Ngene, A.A. (2011) Effects of Aluminium-Magnesium Silicate on Newcastle Disease Virus and on Recovery of Infected Chicks. International Journal of Biological and Chemical Sciences, 5, 825-829.
http://dx.doi.org/10.4314/ijbcs.v5i2.72160
Ezeibe, M.C.O., Mbuko, I.J., Okoroafor, O.N., Okonkwo, A.C., Animoke, P.C., Orajaka, L.J.E. and Ngene, A.A. (2009) In Vitro and in Vivo Effects of Aluminum-Magnesium Silicate on Infectious Bursal Disease Virus in Chikens. Animal Science Reporter, 3, 132-137.
[16]
Ezeibe, M.C.O. and Ogbonna, I.J. (2015) Enhancing Efficacy of Antimicrobials with the Medicinal Synthetic Aluminum-Magnesium Silicate, for Prevention and Treatment of Resistant Infections. BJMMR, 9, 1-8.
http://dx.doi.org/10.9734/BJMMR/2015/17768
[17]
NAM (2016) Types of Viral Load Tests. www.aidsmap.com
[18]
Marck, F., Werner, H., Alex, K., Peter, O., Milos, O., Ruedi, L., Rainer, W. and Richard, W.C. (1999) Highly Sensitive Methods for Quantitation of Human Immunodeficiency Virus Type 1 RNA from Plasma, Cells and Tissues.
www.jcm.asm.org
[19]
Ezeibe, M.C.O. and Ogbonna, I.J. (2016) Medicinal Synthetic Aluminum-Magnesium Silicate {Al4(SiO4)3 + 3Mg2SiO4 →2Al2Mg3(SiO4)3}—A Highly Active Anti-Retroviral Medicine. World Journal of AIDS, 6, 42-46.
http://dx.doi.org/10.4236/wja.2016.62006
[20]
Ashwini, S., Madhuri, T., Philip, R.A. and Ramesh, P. (2010) A Review on Peripheral Blood CD4-T Lymphocyte Counts in Healthy Adult Indians. Indian Journal of Medical Research, 132, 667-675.
[21]
World Health Organization (2004) Consultation on Technical and Operational Recommendations for Scale-Up of Laboratory Services and Monitoring HIV Antiretroviral Therapy in Resource-Limited Settings. WHO Office, Geneva.
